Moreover, origin tissues can predict KRAS missense mutations; KRAS G12D accounted for ∼25%–40% of all KRAS mutations in CRC and PDAC, whereas KRAS G12C accounted for >40% of all KRAS mutations in lung adenocarcinoma [10, 12, 13] (Figure 1). The gene discussed is KRAS; the disease is lung adenocarcinoma.